Infliximab is effective in corticosteroid-refractory ulcerative colitis
As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.
Risk factors for intra-abdominal abscesses in Crohn’s disease
As reported in Digestion, uncontrolled CRP at week 14 of therapy with infliximab (OR=1.36) and early loss of response to infliximab (OR=5.36) are independent risk factors for intra-abdominal abscesses in patients with Crohns disease.
Calcium reduces CRC risk
As reported in the International Journal of Cancer, there is an 8% reduction in CRC risk with each 300 mg/d increase in calcium intake based on 15 studies involving 12305 patients who took 250-1900 mg of calcium/day over a 3.3-16 year follow-up period. The beneficial effect extended beyond 1000 mg/d.